Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 6,433 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin to Skin Clear all
Withdrawn Phase 2 Interventional

A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata

NCT01917058
View directory record Official record
Conditions
Alopecia Areata
Interventions
Abatacept, placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

NCT02941926
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Letrozole, Goserelin, Leuprolide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
71
States / cities
Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

NCT04530344
View directory record Official record
Conditions
Vitiligo
Interventions
ruxolitinib, Vehicle
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
44
States / cities
Hoover, Alabama • Gilbert, Arizona • Fountain Valley, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)

NCT00773734
View directory record Official record
Conditions
Psoriasis, Plaque-type Psoriasis
Interventions
Apremilast 10mg, Apremilast 20mg, Apremilast 30 mg, Placebo, Apremilast 30mg
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
20
States / cities
Fresno, California • Los Angeles, California • Redwood City, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 22, 2026, 5:57 AM EDT
Completed No phase listed Observational

Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib

NCT06083038
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Alpelisib, FreeStyle Libre 2 Continuous Glucose Monitor
Drug · Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Timeline
2023 – 2026
U.S. locations
1
States / cities
Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 22, 2026, 5:57 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

NIR Hypoxia Imaging of Breast Tumor Response to Neoadjuvant Chemotherapy in Vivo

NCT01934114
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
25 Years to 76 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Combination Treatment for Moderate to Severe Acne

NCT01206348
View directory record Official record
Conditions
Acne
Interventions
Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide
Drug
Lead sponsor
Medicis Global Service Corporation
Industry
Eligibility
12 Years to 30 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
10
States / cities
Birmingham, Alabama • Santa Monica, California • Hockessin, Delaware + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea

NCT03276936
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
FMX103 1.5%
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
79
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 72 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 22, 2026, 5:57 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

NCT04274933
View directory record Official record
Conditions
Breast Cancer, Cancer
Interventions
Venetoclax, Capecitabine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
11
States / cities
Joliet, Illinois • Boston, Massachusetts • Minneapolis, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility Study: Evaluate the Effectiveness of Using a Topical Anesthetic Prior to Ultherapy™ Treatment

NCT01708447
View directory record Official record
Conditions
Skin Laxity
Interventions
L.M.X.4.® cream, A placebo cream, Ulthera System Treatment
Drug · Other · Device
Lead sponsor
Ulthera, Inc
Industry
Eligibility
30 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream

NCT03892564
View directory record Official record
Conditions
Phototoxicity
Interventions
MC2-01 Cream, irradiation, MC2-01 Cream, no irradiation, MC2-01 vehicle, irradiation, MC2-01 vehicle, no irradiation, Control, irradiation
Drug
Lead sponsor
MC2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Work Interventions to Improve Employment Outcomes for Persons With Rheumatoid Arthritis and Osteoarthritis

NCT00485914
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis
Interventions
On-site work evaluation, Educational material
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 60 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 1 Interventional

A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma

NCT06153238
View directory record Official record
Conditions
Melanoma
Interventions
GME751, Keytruda - EU, Keytruda - US
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Orange, California • Clermont, Florida • Orange City, Florida
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 22, 2026, 5:57 AM EDT
Terminated Phase 4 Interventional Results available

Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients?

NCT03262038
View directory record Official record
Conditions
Pruritus, Nausea/Vomiting
Interventions
Ondansetron, Placebo Comparator
Drug
Lead sponsor
University of Michigan
Other
Eligibility
3 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 1 Interventional

Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp

NCT01836367
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol Mebutate 0.015%
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 22, 2026, 5:57 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Treatment to Lift Facial Lax Skin and Improve Facial Wrinkles Using Precise and Lift Applicators

NCT06333067
View directory record Official record
Conditions
Lax Skin
Interventions
Sofwave
Device
Lead sponsor
Sofwave Medical LTD
Industry
Eligibility
35 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
La Mesa, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Not applicable Interventional Results available

Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions

NCT04547998
View directory record Official record
Conditions
Vitiligo
Interventions
Control Intervention (UVB), Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)
Device
Lead sponsor
Avita Medical
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Irvine, California • Sacramento, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.

NCT01437384
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura (ITP)
Interventions
E5501
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 2 Interventional Results available

Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer

NCT01299038
View directory record Official record
Conditions
Breast Cancer
Interventions
rosuvastatin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 22, 2026, 5:57 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

NCT02905331
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Ocala, Florida • Rolling Meadows, Illinois • Plainfield, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 22, 2026, 5:57 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

NCT04908202
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
33
States / cities
Gilbert, Arizona • Jonesboro, Arkansas • Fontana, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 22, 2026, 5:57 AM EDT
Terminated Phase 3 Interventional Results available

An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

NCT03749447
View directory record Official record
Conditions
Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney
Interventions
Bardoxolone methyl
Drug
Lead sponsor
Biogen
Industry
Eligibility
12 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
61
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 22, 2026, 5:57 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

NCT05985655
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC)
Interventions
GTAEXS617, SoC
Drug
Lead sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Grand Rapids, Michigan • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 22, 2026, 5:57 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 22, 2026, 5:57 AM EDT